Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
2.080
+0.240 (13.04%)
At close: Nov 21, 2024, 4:00 PM
2.000
-0.080 (-3.84%)
After-hours: Nov 21, 2024, 5:58 PM EST
Quince Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Quince Therapeutics stock have an average target of 9.67, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 364.90% from the current stock price of 2.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for QNCX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 |
|---|---|
| Strong Buy | 3 |
| Buy | 0 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +476.92% | Nov 12, 2024 |
| Maxim Group | Maxim Group | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +188.46% | Nov 7, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +428.85% | Oct 29, 2024 |
| EF Hutton | EF Hutton | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +476.92% | Oct 22, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.16
from -0.84
EPS Next Year
-0.32
from -1.16
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | n/a | n/a |
| Avg | n/a | n/a |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.20 | -0.33 | -0.15 |
| Avg | -1.16 | -0.32 | -0.14 |
| Low | -1.12 | -0.30 | -0.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.